CME Group CME

Financial Services · Financial - Data & Stock Exchanges · Synthos Deep Dive · 2026-07-03

$236.60

Buy — Core

Risk 3Growth 7Exponential 2Fair value $309 $215–$384

—

At a glance

Verdict	Buy — Core — systematic Synthos tier
Price (2026-07-02)	$236.60 · market cap ~$85.7B
Synthos scores (0–10)	Downside Risk 3 · Growth Quality 7 · Exponential Potential 2
Synthos fair value (base case)	~$309 → +31% (plus ~4.8% dividend) · full range $215 (bear) – $384 (bull)
Street consensus	$320.67 (high $353 / low $302; 0 Strong-Buy · 15 Buy · 16 Hold · 5 Sell → Hold) — context, not our anchor
Valuation	20× trailing EPS · 19× FY26E · 18× FY27E · 15× FY30E · EV/S 12.8× · EV/EBITDA 14.5× · div yield 4.8%
Exponential Potential	2/10 · Low — ~7% forward EPS CAGR and decelerating; a mature toll-road, not a multibagger
Technicals	Downtrend — $237, −28% off 52-wk high, below 50/200-DMA, RSI 33, −14% 12-mo (SPY +21%)
Conviction	Moderate — 4 net-bullish voices, 14 reconciled claims (top skill 1.0: Business Breakdowns, Odd Lots)
Position sizing	Value/quality satellite, ~2–4%, scale in on weakness
Next catalyst	2026-07-22 Q2'26 earnings (Street EPS $3.00)
Single biggest risk	Rate-cut cycle + crypto perpetual-futures displacement compress volumes and the rich rate-per-contract

One-line thesis. CME is the toll-booth on global derivatives — an 88%-EBITDA-margin, net-cash monopoly with vertically integrated clearing — that the market has marked down 28% on rate-cut and crypto-displacement fears; at 20× trailing and a 4.8% dividend the risk/reward has flipped attractive for a Tactical buy, but ~7% forward growth caps it well short of a core-compounder call.

◆ Synthos call — Buy — Core CME is attractively priced but a top-tier compounder — own it now and add on dips toward the 50-day (~$213–$237).

Downside Risk (lower = safer)

3/10 · Low

Net cash, beta 0.28, near-monopoly clearing — but full 20× P/E on ~7% growth and a live −28% drawdown.

Growth Quality

7/10 · High

88% EBITDA margin & fortress moat, but only ~7% forward EPS CAGR and single-digit revenue growth.

Exponential Potential

2/10 · Low

Mature, decelerating mega-cap in a mostly-fixed TAM; crypto/prediction-market futures are real but small optionality.

◆ Target entry zone $213 – $237 accumulate in this band; ideal adds on a dip toward the 200-day average near $213, keeping roughly a 23% margin below our $309 base-case fair value

⚖ Reverse-DCF cross-check Market-implied growth ≈ 14%/yr To justify today’s $237, earnings would have to compound roughly 14% a year for 10 years (9% discount rate). Analysts forecast ~8%/yr, so the market is pricing in MORE than what the Street expects.

What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)

Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.

Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.

WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.

HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.

AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.

In plain English

CME Group runs the world's biggest futures and options marketplaces — think of it as the toll booth every trader, farmer, bank, and fund has to pass through to bet on or hedge interest rates, oil, gold, stock indexes, wheat, and increasingly crypto. It also owns the "clearing house" that guarantees those trades settle. It collects a tiny fee on every contract, and there are billions of contracts, so the profits are enormous — it keeps roughly 62 cents of every revenue dollar as net profit.

Is the stock cheap or expensive? For this company, fairly cheap right now. It has fallen about 28% from its high because investors worry that lower interest rates and new crypto trading venues will slow it down. That fear has pushed the price down to about 20× earnings with a 4.8% dividend — a good price for such a durable business. Our verdict is Buy — Tactical: buy it for the discount and the dividend, but know it's a slow, steady grower, not a rocket.

Here's what our three scores mean in everyday terms:

Downside Risk 3/10 (fairly safe). It has more cash than debt, its stock barely moves with the market (very low beta), and almost nobody can compete with it — but it's already had a rough year, so the easy money is being paid for its dividend and patience.
Growth Quality 7/10 (good). A fantastically profitable, unbreakable business — just not a fast-growing one.
Exponential Potential 2/10 (low). It's a big, mature company in a market that grows slowly. Don't expect it to double quickly.

The one big worry: if interest rates keep falling and traders drift to newer crypto "perpetual futures" venues, CME's trading volumes and the fat fee it earns per contract could shrink.

Price & moving averages 12 months · 50 & 200-day averages · 52-week range

Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.

Bollinger Bands 20-day average ± 2 standard deviations

The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.

RSI (14) momentum gauge · 0–100

Above 70 (red band) = overbought, below 30 (green band) = oversold. Currently 40.

MACD 12 / 26 / 9 · trend & momentum

Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.

Relative performance vs S&P 500 & its sector (XLF (sector)), set to 100 a year ago

Solid = CME · dashed = S&P 500 · dotted = XLF (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.

Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate

Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.

Key stats an RIA wants

Price$236.60

Market cap$86B

P/E trailing10×

P/E FY26E / FY27E19× / 18×

EV / Sales12.8×

EV / EBITDA14.5×

Gross margin86.3%

Net margin62.8%

Dividend yield4.75%

Beta0.276

52-wk range$219 – $326

RSI(14)33

50 / 200-DMA$269 / $280

12-mo return+-14% (SPY +21%)

Street target$321 ($302–$353)

Analyst grades15 Buy · 16 Hold · 5 Sell

FMP ratingB+

Next earnings2026-08-05

What the experts actually said 14 traceable claims on CME · showing the highest-conviction voices

“CME is best-in-class derivatives exchange with dominant liquidity and vertically integrated clearing; a durable, high-quality compounder.”

Business Breakdownsbullishconviction 852025-08-17business_breakdowns-GlNFrhxke3E:6f3f1e7dfc

“Regulated KYC exchanges (Kalshi, CME, Polymarket regulated) are far safer from insider trading than DeFi crypto platforms; SIG only plays regulated space.”

Odd Lotsbullishconviction 802026-06-06odd_lots-IblwpXSh6xM:875f13657c

“CME is the king of exchanges; the selloff on perpetual-futures displacement fears is overdone — wants to buy it.”

Compound And Friendsbullishconviction 70n/acompound_and_friends-QzbZSLClQag:e2ba15852e

“CME's new Sui futures product gives large Wall Street traders a key mechanism to move size in the Sui token — a small club beyond Bitcoin.”

Real Visionbullishconviction 702026-05-24real_vision-KMq0S1WSlng:c5eee1d1b2

Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.

1. What it is

CME Group (NASDAQ: CME) is the world's largest and most diversified derivatives exchange and clearing house, founded in Chicago in 1898. It operates the marketplaces (CME, CBOT, NYMEX, COMEX) where futures and options trade across six asset classes — interest rates, equity indices, FX, energy, agriculture, and metals — plus the CME Globex electronic platform, BrokerTec (fixed income) and EBS (FX). Critically, it also owns CME Clearing, one of the world's leading central counterparties, which verifies, settles and guarantees every trade. That vertical integration — matching engine + clearing + data — is the moat. Fiscal year ends December 31.

Revenue mix (FY2025, from filings):

By product line: Clearing & transaction fees $5.28B (81%) · Market data $803M (12%) · Other $436M (7%). The business is overwhelmingly transaction-volume-driven, so average daily volume (ADV) and the rate-per-contract are the two numbers that move the stock.
By geography: FMP does not provide a geographic segmentation split for CME. Management's Q1'26 release notes non-US ADV hit a record 11.4M contracts (up 30% YoY), with APAC +33% and EMEA +29% — international is the faster-growing slice.

The strategic story the KB keeps returning to is CME as the regulated home for new-asset-class derivatives — crypto (Bitcoin, Ether, and now Sui futures), even prediction-market-adjacent products — where its regulated, KYC status is a feature institutions require.

2. The expert thesis — why the panel is (mildly) bullish (traceable)

CME has 14 traceable KB claims across 4 net-bullish voices — moderate breadth, high skill (top voices carry selection-skill 1.0). This is a quality-and-valuation thesis, not a high-conviction breadth stampede. Three threads:

Best-in-class, durable monopoly. Business Breakdowns (business_breakdowns-GlNFrhxke3E:6f3f1e7dfc, bullish, conviction 85) frames CME as the "best-in-class derivatives exchange with dominant liquidity and vertically integrated clearing — a durable, high-quality compounder." This is the spine of the thesis: liquidity begets liquidity, and the clearing house is a regulatory-grade barrier.
The crypto-displacement selloff is overdone. Compound & Friends (compound_and_friends-QzbZSLClQag:e2ba15852e, bullish, conviction 70): CME is "the king of exchanges; the selloff on perpetual-futures displacement fears is overdone — wants to buy it." This directly names the reason the stock is down 28% and calls it a buying opportunity.
Regulated status is the edge in new asset classes. Odd Lots (odd_lots-IblwpXSh6xM:875f13657c, bullish, conviction 80): regulated KYC exchanges (CME among them) are "far safer from insider trading than DeFi crypto platforms." Real Vision (real_vision-KMq0S1WSlng:c5eee1d1b2, bullish, conviction 70): CME's new Sui futures give large Wall Street traders a regulated venue to move size in a token beyond Bitcoin — evidence CME keeps annexing new derivatives niches.

Honest composite note. Breadth here is moderate (4 voices, 14 claims), not the deep panel behind a mega-conviction name. The bull case leans on two pillars — an unassailable moat and a beaten-down price — more than on accelerating growth. There is no cautionary voice loud enough to flip the sign, but the thin-ish breadth is exactly why this is Tactical, not Core.

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

Score	0–10	The read
Downside Risk (lower = safer)	3 · Low-Moderate	Net cash (−$666M net debt), beta 0.28, near-monopoly clearing and a 4.8% dividend cushion — offset by a full 20× P/E on ~7% growth and a live −28% drawdown that says the market smells slowing volumes.
Growth Quality	7 · High	88% EBITDA margin, 63% net margin, ROE 15%, unbreakable moat — elite quality, but only ~7% forward EPS CAGR and single-digit revenue growth keep it out of the 9-club.
Exponential Potential	2 · Low	~7% forward growth and decelerating; a mature $86B toll-road in a slow-growing TAM. Crypto/prediction-market futures are real optionality but too small to move a $6.5B revenue base soon.

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores summarize them.

Case	Key assumptions	Fair value
Bull	Volatility stays elevated ("risk is the new normal"); ADV and rate-per-contract hold records; crypto/new-product optionality gains credibility. FY27E EPS beats to ~$13.70 (Street high); multiple re-rates to ~28× (its historical premium).	~$384 (+62%)
Base (our anchor)	Estimates roughly hit — FY27E EPS $12.89; a durable monopoly compounder earns back a ~24× multiple as drawdown fears fade.	~$309 (+31%)
Bear	Rate cuts crush interest-rate ADV; perpetual-futures venues chip at crypto/equity volume; rate-per-contract erodes. FY27E EPS misses to ~$11.93 (Street low); multiple de-rates to ~18×.	~$215 (−9%)

Synthos fair value = the base case, ~$309 (+31%) before the ~4.8% dividend, with the full $215–$384 span as the honest range. This anchor sits just below the Street's $320.67 consensus — we are constructive but not more so than the sell side, and our bear ($215) is below the Street's $302 low because we take the rate-cut/crypto-displacement risk seriously. This is a tracked call — the Forecaster Scorecard grades it once it matures.

4. Exponential Potential

Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). CME is a textbook mature compounder with essentially no exponential profile:

Forward growth: revenue CAGR FY25→FY30E ~5.9% ($6.52B → $8.68B); EPS CAGR ~7.0% ($11.18 → $15.70) — steady, high-single-digit, not exponential.
Acceleration (the 2nd derivative) is roughly flat-to-negative: revenue +6.4% (FY25) → +7.9% (FY26E) → +4.6% (FY27E). No inflection; volume-driven exchanges grow with market activity and rate volatility, both of which mean-revert.
Room to run: the derivatives TAM is large but mature and already largely CME's — it is the incumbent, not a share-taker with open field. At $86B market cap in a slow-growing pie, there is no law-of-large-numbers and no accelerant. Crypto derivatives and prediction-market-adjacent products (real_vision-KMq0S1WSlng:c5eee1d1b2, odd_lots-IblwpXSh6xM:875f13657c) are genuine new niches but far too small to bend a $6.5B revenue base near-term.
Reinvestment runway: minimal capex (capex/revenue ~1.3%) — this is a cash-return machine, not a reinvestment-for-growth story. It pays out ~96% of earnings as dividends.

Exponential Potential: Low (2/10). Own CME for its moat, its cash return, and a discounted entry — not for growth. That is the honest framing and the reason the verdict is Tactical, not a growth-flagship Core.

5. Financials (real numbers — FMP annual/quarterly)

Revenue: FY25 $6.52B, +6.4% (FY24 $6.13B, +9.9% on FY23 $5.58B). Steady mid-single-digit growth on record volumes.
Quarterly trajectory: Q1'25 $1.64B → Q2 $1.69B → Q3 $1.54B → Q4 $1.65B → Q1'26 $1.88B (a record, +14% YoY; ADV +22% to a record 36.2M contracts, per management).
Margins: gross 86.3% TTM, EBITDA 88.6% TTM, operating ~65.6%, net 62.8% TTM — among the highest margins in the entire S&P 500. A near-pure toll-take model.
Earnings: net income $4.04B FY25 (+15% on FY24 $3.53B); GAAP EPS $11.18 (diluted $11.16). Q1'26 GAAP diluted EPS $3.18, adjusted $3.36.
Cash flow: operating CF $4.28B, capex just −$84M, FCF $4.19B FY25 (FCF yield ~5.0%). Near-perfect FCF conversion — the hallmark of an asset-light exchange.
Balance sheet: total debt $3.76B against $4.42B cash → net cash of ~$666M; net-debt/EBITDA 0.17× (effectively net-cash). Fortress. (Note: total assets appear enormous — ~$198B — because CME's balance sheet consolidates clearing-member performance-bond/collateral cash, an offsetting liability, not operating leverage.)

6. Valuation — priced in or room?

Unusually for a wide-moat monopoly, CME is not richly priced today: 20× trailing EPS, 14.5× EV/EBITDA, 12.8× EV/sales, and a 4.8% dividend yield after a 28% drawdown. On live consensus the forward P/E is 19× (FY26E) → 18× (FY27E) → 15× (FY30E) — modest de-rating even at a flat price. Against ~7% EPS growth, a ~19× forward multiple is a PEG near ~2.7 — not statistically cheap on growth, but for a business with 88% EBITDA margins, net-cash, and monopoly durability, a low-20s multiple is defensible and the stock currently trades below that. The FMP letter rating is B+ (DCF and ROE scores strong; P/E and P/B scores weak — i.e., quality high, headline multiples the concern). Street targets (context): consensus $320.67, high $353, low $302 — notably, every street target sits above today's $237, i.e. the sell side already views the drawdown as an overshoot. Our $309 base is slightly below consensus (we haircut for rate-cut risk). Not a screaming bargain, but a quality monopoly at a rare discount + a 4.8% yield — the setup that defines a Tactical buy.

7. Technicals (from the tech block)

Trend: down. $236.60 sits below the 50-DMA ($269) and 200-DMA ($280), with the 50 below the 200 (death-cross posture). MACD −12.9 (negative). This is a downtrend, full stop.
Location: −27.5% off the 52-week high ($329), only +8.2% off the 52-week low ($219) — near the bottom of its range, max drawdown −27.5%.
Momentum: RSI(14) 33 — near oversold (<30), consistent with a washed-out, beaten-down name rather than a stretched one.
Relative strength (the tell, and it's negative): CME −14.1% 12-mo vs SPY +20.6% and QQQ +30.3%; −20.3% 3-mo vs SPY +13.7%. A persistent, severe laggard — the market has been actively de-rating it.
Read: technicals contradict the fundamental thesis — this is a falling knife, not a confirmed uptrend. That is precisely why the verdict is Tactical and the guidance is to scale in: the value is real, but there is no chart support yet and momentum is against you. A confirmed reclaim of the 50-DMA (~$269) would be the technical green light; a break below the $219 low is the tripwire.

8. Moat & competitive position

CME's moat is a rare, self-reinforcing triple: (1) a liquidity network effect — traders go where the liquidity is, and CME's benchmark contracts (SOFR, E-mini S&P, WTI, gold, Treasuries) are the deepest pools in the world, so liquidity begets liquidity; (2) vertically integrated clearing — owning CME Clearing means the margin/collateral, netting and cross-margining efficiencies ($85B+ average daily margin savings per management) are captive and hard to replicate; (3) regulatory-grade barriers — a new entrant must build not just a matching engine but a CFTC-regulated clearing house. The KB voices lean hard on this (business_breakdowns-GlNFrhxke3E:6f3f1e7dfc, odd_lots-IblwpXSh6xM:875f13657c). The genuine threats: crypto perpetual-futures venues displacing volume (the fear driving the drawdown, which Compound & Friends compound_and_friends-QzbZSLClQag:e2ba15852e calls overdone) and a lower-rate regime shrinking interest-rate ADV.

Peer set (FMP-supplied; market cap): Intercontinental Exchange (ICE) $75B — the closest direct exchange comp; Nasdaq (NDAQ) $48B; Moody's (MCO) $86B; Coinbase (COIN) $44B — the crypto-native threat/frenemy; Marsh & McLennan $90B; Brookfield Asset Mgmt $73B; plus several banks (BMO, BNS, Mizuho, ICICI) that are peers only in the loose "financials" sense. Against ICE and NDAQ, CME is the largest, highest-margin, and most clearing-integrated — and now trades at a discount to its own history.

9. Management, capital allocation & guidance

Capital allocation: a disciplined cash-return machine. FY25 paid $3.93B in dividends (regular + a variable special; ~96% payout) and repurchased $266M of stock; capex is negligible (~$84M). The stated $11.25 trailing dividend = ~4.8% yield. This is the correct policy for a low-reinvestment monopoly — return the cash — but it also confirms there is no internal growth engine to fund.
Insider activity: the most recent Form 4 cluster (filed 2026-06-29) is routine director equity awards at $225, plus a small director open-market purchase (William Shepard, ~$230.57). No alarming discretionary selling in the sampled window; a modest insider buy near the lows is a mild positive.
Management's own guidance (half-weighted — they talk their book): the SEC 8-K Item 2.02 earnings release (filed 2026-04-22, Q1'26) was retrieved and reads as a genuine earnings release. CME does not issue explicit numeric revenue or EPS guidance. Management (Chairman/CEO Terry Duffy) framed the outlook qualitatively: "In a world in which risk has become the new normal, 2026 is off to a record-breaking start… Robust demand drove Q1 ADV up 22% to a record 36.2M contracts, including records in all six asset classes… innovation remains central to our growth strategy." Treat as self-interested color, half-weighted: the substantive tell is record ADV and a record $0.652 rate-per-contract, which cuts against the volume-displacement bear thesis — but there is no hard forward number to hold them to.

10. Catalysts & what to watch

Next earnings: 2026-07-22 (Q2'26; Street EPS $3.00, revenue ~$1.73B). The key lines: ADV and rate-per-contract — did record Q1 volume hold, or did it fade?
Rate path: Fed rate cuts reduce interest-rate futures/options ADV (CME's largest complex) — the single biggest macro swing factor.
Crypto/new-product traction: Bitcoin/Ether/Sui futures volumes and any prediction-market-adjacent launches — the optionality the bulls (real_vision-KMq0S1WSlng:c5eee1d1b2) are watching, and the displacement fear the bears are.
Cross-margining expansion: the extended FICC cross-margining agreement (management flagged) — an efficiency moat-widener.
Google Cloud migration: management flags duplicative costs during the transition — a margin watch-item.

Thesis tripwires (what would change the call): two consecutive quarters of ADV and rate-per-contract decline together; a technical break below the $219 52-week low; or a credible regulated perpetual-futures competitor taking measurable share.

11. Key risks

Rate-cut cycle (cyclical): interest-rate products are CME's biggest complex; a falling-rate, low-volatility regime shrinks ADV. This is the core cyclical risk and part of what drove the −28% drawdown.
Crypto perpetual-futures displacement (secular): newer venues could siphon crypto and even equity-index volume; the bulls call it overdone (compound_and_friends-QzbZSLClQag:e2ba15852e) but it is the market's active fear.
Rate-per-contract erosion: a mix shift toward lower-fee products or incentive programs compresses the ~$0.65 rate-per-contract — a subtle margin lever the bear case leans on.
Valuation is "cheap-for-CME," not cheap: 20× / ~2.7 PEG leaves limited absolute-value cushion if growth stalls.
Payout leaves no growth optionality: ~96% payout means the equity story is the dividend + modest EPS growth; a dividend cut (unlikely, but rate-sensitive on the special) would hit the thesis hard.
Thin KB breadth: 4 voices / 14 claims is moderate conviction — less corroboration than a core-flagship name.

12. Verdict, position sizing & monitoring

Buy — Tactical. CME is a genuinely elite business — an 88%-EBITDA-margin, net-cash, monopoly toll-road with vertically integrated clearing (business_breakdowns-GlNFrhxke3E:6f3f1e7dfc) — that the market has marked down 28% on rate-cut and crypto-displacement fears the KB's sharpest voices call overdone (compound_and_friends-QzbZSLClQag:e2ba15852e). At 20× trailing, ~19× forward, a 4.8% dividend, and a base-case fair value of ~$309 (+31% before the dividend), the risk/reward has flipped attractive. What keeps it Tactical rather than Core: ~7% forward growth (Exponential Potential just 2/10), a still-broken chart (below both moving averages, RSI 33), and only moderate KB breadth.

Sizing: value/quality satellite, ~2–4%. Because the technicals are still in a downtrend, scale in on weakness (starter now, adds on stabilization or a 50-DMA reclaim) rather than a single lump. The 4.8% dividend pays you to wait.
Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $236.60.
Single biggest risk: a sustained rate-cut cycle plus crypto perpetual-futures displacement compressing both volume and the rate-per-contract at once.

Provenance & disclosures

Traceability: 14 KB claims, breadth 4 net-bullish voices, top skill 1.0 (Business Breakdowns, Odd Lots), last claim 2026-06-06 — all reconciled to real claim_ids (cited inline). Fabricated conviction is structurally impossible (claim-ID reconciliation).
Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · expert claims through 2026-06-06. Forward figures are analyst consensus (FMP), labeled as estimates.
Management caveat: CME issues no explicit numeric guidance; the Q1'26 8-K commentary is management's own book, half-weighted by design.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").